The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications

CNS Drugs

Volumn 16, Issue 5, 2002, Pages 339-352

  Perry, George ^a   Sayre, Lawrence M ^a   Atwood, Craig S ^a   Castellani, Rudolph J ^a   Cash, Adam D ^a   Rottkamp, Catherine A ^a   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CATALASE; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; ENZYME; FREE RADICAL; IRON; MANGANESE; MANGANESE SUPEROXIDE DISMUTASE; PEROXIDASE; ZINC;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN FUNCTION; BRAIN METABOLISM; DEGENERATIVE DISEASE; GENE THERAPY; HOMEOSTASIS; HUMAN; METAL METABOLISM; NEUROPATHOLOGY; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0036113819     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216050-00006     Document Type: Review

References (121)

1. How important is oxidative damage? Lessons from Alzheimer's disease
2. Widespread peroxynitrite-mediated damage in Alzheimer's disease
3. Myeloperoxidase and horse-radish peroxidase catalyze tyrosine nitration in proteins from nitrite and hydrogen peroxide
4. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
5. Abnormal localization of iron regulatory protein (IRP) in Alzheimer disease
6. Evidence for a novel heme-binding protein, HasAh, in Alzheimer disease
7. Sequestration of iron by Lewy bodies in Parkinson's disease
8. Lipoperoxidation is selectively involved in progressive supranuclear palsy
9. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain
10. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin?
11. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders
12. The copper chaperone for superoxide dismutase
13. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders
14. The cellular prion protein binds copper in vivo
15. Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein
16. Induction of heme oxygenase-1 and neuronal nitric oxide synthase in Doppel-expressing mice devoid of prion protein: Implications for Doppel function
17. Quinone reductase (NQOI), a sensitive redox indicator, is increased in Alzheimer's disease
18. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease
19. Protein disulfide isomerase in Alzheimer disease
20. Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione
21. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress
22. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice
23. Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice
24. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase
25. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury
26. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1
27. Hindlimb motor neurons require Cu/Zn superoxide dismutase for maintenance of neuromuscular junctions
28. Oxidative stress and iron are implicated in fragmenting vacuoles of Saccharomyces cerevisiae lacking Cu,Zn-superoxide dismutase
29. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis
30. Reactions of hydrogen peroxide with familial amyotrophic lateral sclerosis mutant human copper-zinc superoxide dismutases studies by pulse radiolysis
31. The familial amyotrophic lateral sclerosis-associated amino acid substitutions E100G, G93A, and G93R do not influence the rate of inactivation of copper- and zinc-containing superoxide dismutase by H2O2
32. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants
33. Subunit asymmetry in the three-dimensional structure of a human CuZnSOD mutant found in familial amyotrophic lateral sclerosis
34. Release of copper ions from the familial amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutants
35. The free radical-generating function of a familial amyotrophic lateral sclerosis-associated D90A Cu,Zn-superoxide dismutase mutant
36. Reexamination of the mechanism of hydroxyl radical adducts formed from the reaction between familial amyotrophic lateral sclerosis-associated Cu,Zn superoxide dismutase mutants and H2O2
37. Loss of in vitro metal ion binding specificity in mutant copper-zinc superoxide dismutases associated with familial amyotrophic lateral sclerosis
38. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase
39. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite
40. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis
41. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis
42. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: Molecular mechanisms of neuronal death and protection
43. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
44. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis
45. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice
46. Aberrant copper chemistry as a major mediator of oxidative stress in a human cellular model of amyotrophic lateral sclerosis
47. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease
48. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal
49. Effects of copper on survival of prion protein knockout neurons and glia
50. Copper stimulates endocytosis of the prion protein
51. Prion protein glycosylation is sensitive to redox change
52. Prion protein selectively binds copper(II) ions
53. Raman spectroscopic study on the copper(II) binding mode of prion octapeptide and its pH dependence
54. Copper binding to the prion protein: Structural implications of four identical cooperative binding sites
55. Strain-specific prion-protein conformation determined by metal ions
56. Consequences of manganese replacement of copper for prion protein function and proteinase resistance
57. The octapeptide repeat region of prion protein binds Cu(II) in the redox-inactive state
58. Prion protein expression and superoxide dismutase activity
59. Normal prion protein has an activity like that of superoxide dismutase
60. Selective oxidation of methionine residues in prion proteins
61. Prion protein-deficient neurons reveal lower glutathione reductase activity and increased susceptibility to hydrogen peroxide toxicity
62. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
63. Iron, melanin and dopamine interaction: Relevance to Parkinson's disease
64. The role of iron in senescence of dopaminergic neurons in Parkinson's disease
65. On the functions of monoamine oxidase, the emotions, and adaptation to stress
66. Astrocytes, brain aging, and neurodegeneration
67. Astrocyte mitochondria: A substrate for iron deposition in the aging rat substantia nigra
68. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
69. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy
70. Biochemistry as neurodegeneration
71. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease
72. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease
73. New reaction pathways of dopamine under oxidative stress conditions: Nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6,7-dihydroxytetrahydroisoquinoline
74. Neurodegeneration with brain iron accumulation, type 1 is characterized by α-, β-, and γ-synuclein neuropathology
75. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
76. Copper(II)-induced self-oligomerization of α-synuclein
77. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
78. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease
79. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease
80. Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism
81. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress
82. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1
83. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse
84. Neuron loss in APP transgenic mice
85. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain
86. Advanced Maillard reaction end products are associated with Alzheimer disease pathology
87. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with dinitrophenylhydrazine
88. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease
89. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer disease
90. In Alzheimer disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification
91. Copper, iron and zinc in Alzheimer's disease senile plaques
92. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy
93. In situ redox catalysis by neurofibrillary tangles and senile plaques in Alzheimer disease: A central role for bound transition metals
94. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice
95. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease
96. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide
97. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis
98. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation
99. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion
100. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of Aβ using physiological concentrations
101. Promotion of transition metal-induced reactive oxygen species formation by β-amyloid
102. The stabilization of ferrous iron by a toxic β-amyloid fragment and by an aluminum salt
103. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction
104. Cu(II) potentiation of Alzheimer Aβ neurotoxicity
105. Evidence of oxidative stress in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer disease: A chronic oxidative paradigm for testing antioxidant therapies in vivo
106. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid β-peptide(1-42)
107. Amyloid β peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides
108. Redox-active iron mediates amyloid-β toxicity
109. Mechanisms of neurotoxicity associated with amyloid β deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: A critical appraisal
110. Methionine residue 35 is important in amyloid β-peptide-associated free radical oxidative stress
111. Copper-binding amyloid precursor undergoes a site-specific fragmentation in the reduction of hydrogen peroxide
112. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice
113. Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome
114. Oxidative damage is the earliest event in Alzheimer disease
115. Increasing amyloid β 42 deposition is associated with decreasing neuronal RNA oxidation in Down's syndrome and familial Alzheimer's disease
116. How important is oxidative damage? Lessons from Alzheimer disease
117. Amyloid-β junkies
118. Pharmacological treatment of cognitive deficits in Alzheimer's disease
119. Treatment of Alzheimer's disease with clioquinol
120. Intramuscular desferrioxamine in patients with Alzheimer's disease
121. Reactive oxygen species mediate cellular damage in Alzheimer disease